Isoindolinone and indazole compounds for the degradation of EGFR
MYPI2026003133A0Undetermined Publication Date: 2021-06-20C4 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2026003133
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-20
- Filing Date
- 2020-12-18
- Publication Date
- 2021-06-20
Abstract
ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR ABSTRACT The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers. [No Available Figure]
Need to check novelty before this filing date? Find Prior Art
